(GLP)

• Average Fat Loss: Standard 2.4 mg doses continue to show an average of 15% total body loss over 68 weeks.
• High-Dose (7.2 mg) Approval: Authorized in early 2026, the 7.2 mg variant has shown a mean weight reduction of 20.7%. Data from the STEP UP trials indicate patients are 2.4 times more likely to hit a 25% weight loss milestone on this dose.
• The “Food Noise” Effect: Data confirms semaglutide targets the hypothalamus to mute intrusive thoughts about eating, which is now recognized as a primary driver of long-term success.

Cardiovascular Benefits (The SELECT Trial Legacy)

Recent 2026 analyses of the SELECT trial have solidified semaglutide’s role in heart health, regardless of how much Fat is actually lost.

• Benefit Category | Key Data Point: MACE Reduction | 20% reduction in Major Adverse Cardiovascular Events (heart attack, stroke, death).
• Independence from Weight | Cardioprotective effects persist even in patients who experience minimal weight loss, suggesting direct vascular benefits.
• Systemic Inflammation | Significant reduction in C-reactive protein (CRP) levels, a key marker of heart disease risk.

Kidney and Liver Health (New Indications)

Reporting in 2026 highlights semaglutide as a “cardio-kidney-metabolic” survival therapy.

Chronic Kidney Disease (CKD)
Data from the FLOW trial (updated April 2026) shows:

• 24% reduction in the risk of kidney disease progression and death from kidney-related causes.
• Significant slowing of eGFR decline (loss of kidney function) across all stages of CKD.
• The greatest survival benefit was found in patients with the most severe kidney damage (UACR > 2000 mg/g).

Liver Health (MASH/NASH)
Semaglutide received expanded indications in early 2026 for Metabolic Dysfunction-Associated Steatohepatitis (MASH):

• Fibrosis Improvement: It has been shown to reduce liver scarring (fibrosis) in adults with stage F2/F3 MASH.
• Fatty Liver Index: In recent trials, semaglutide led to a 28% greater decrease in liver fat compared to placebo.